SRRA insider filings
Sierra Oncology, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-07-01. Screen SRRA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for SRRA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Sierra Oncology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-07-01 | 4 | Sinclair Andrew — Director | Disposition to issuer (D): 1,314,127 @ $55 · Disposition to issuer (D): 1,500 (derivative) · Disposition to issuer (D): 6,874 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 871,125 (derivative) @ $45.98 | EDGAR |
| 2022-07-01 | 4 | Vivo Opportunity, LLC — Director, 10% owner Vivo Opportunity Fund Holdings, L.P. — Director, 10% owner Vivo Capital IX, LLC — Director, 10% owner Vivo Capital Fund IX, L.P. — Director, 10% owner VIVO VENTURES VII, LLC — Director, 10% owner Vivo Ventures Fund VII, L.P. — Director, 10% owner Vivo Ventures VII Affiliates Fund, L.P. — Director, 10% owner | Disposition to issuer (D): 161,712 @ $55 · Disposition to issuer (D): 2,735,853 @ $55 · Disposition to issuer (D): 431,947 @ $55 · Disposition to issuer (D): 324,740 (derivative) @ $0 · Disposition to issuer (D): 1,455,384 (derivative) @ $0 · Disposition to issuer (D): 75,749 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Ashiya Mona — Director, 10% owner | Disposition to issuer (D): 1,511,362 @ $55 · Disposition to issuer (D): 226,704 @ $55 · Disposition to issuer (D): 226,704 @ $55 · Disposition to issuer (D): 1,500 (derivative) @ $0 · Disposition to issuer (D): 6,874 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · +3 more | EDGAR |
| 2022-07-01 | 4 | Aggarwal Gaurav — Director | Disposition to issuer (D): 2,735,853 @ $55 · Disposition to issuer (D): 1,500 (derivative) @ $0 · Disposition to issuer (D): 6,874 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · Disposition to issuer (D): 1,455,384 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Klencke Barbara — Chief Medical Officer | Disposition to issuer (D): 10,000 @ $55 · Disposition to issuer (D): 5,000 @ $55 · Disposition to issuer (D): 11,744 (derivative) @ $0 · Disposition to issuer (D): 2,061 (derivative) @ $0 · Disposition to issuer (D): 11,399 (derivative) @ $0 · Disposition to issuer (D): 1,749 (derivative) @ $0 · +6 more | EDGAR |
| 2022-07-01 | 4 | Jagpal Sukhi — Chief Financial Officer | Disposition to issuer (D): 3,859 (derivative) @ $0 · Disposition to issuer (D): 1,218 (derivative) @ $0 · Disposition to issuer (D): 4,200 (derivative) @ $0 · Disposition to issuer (D): 1,750 (derivative) @ $0 · Disposition to issuer (D): 4,509 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · +5 more | EDGAR |
| 2022-07-01 | 4 | Pelzer Robert — Director | Disposition to issuer (D): 671 (derivative) @ $0 · Disposition to issuer (D): 970 (derivative) @ $0 · Disposition to issuer (D): 625 (derivative) @ $0 · Disposition to issuer (D): 625 (derivative) @ $0 · Disposition to issuer (D): 750 (derivative) @ $0 · Disposition to issuer (D): 16,686 (derivative) @ $0 · +1 more | EDGAR |
| 2022-07-01 | 4 | Cooper Jeffrey H — Director | Disposition to issuer (D): 1,941 (derivative) @ $0 · Disposition to issuer (D): 625 (derivative) @ $0 · Disposition to issuer (D): 625 (derivative) @ $0 · Disposition to issuer (D): 750 (derivative) @ $0 · Disposition to issuer (D): 18,061 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Allen Andrew R — Director, 10% owner | Disposition to issuer (D): 1,650 @ $55 · Disposition to issuer (D): 750 (derivative) @ $0 · Disposition to issuer (D): 1,250 (derivative) @ $0 · Disposition to issuer (D): 625 (derivative) @ $0 · Disposition to issuer (D): 12,030 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Collard Craig A — Director | Disposition to issuer (D): 13,500 @ $55 · Disposition to issuer (D): 10,000 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | DILLY STEPHEN GEORGE — CEO and President, Director | Disposition to issuer (D): 5,000 @ $55 · Disposition to issuer (D): 520,000 (derivative) @ $0 · Disposition to issuer (D): 260,000 (derivative) @ $0 · Disposition to issuer (D): 92,000 (derivative) @ $0 · Disposition to issuer (D): 165,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Thomson Mary Christina — General Counsel | Disposition to issuer (D): 92,000 (derivative) @ $0 · Disposition to issuer (D): 49,000 (derivative) @ $0 · Disposition to issuer (D): 12,900 (derivative) @ $0 · Disposition to issuer (D): 35,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Disposition to issuer (D): 75,000 (derivative) @ $0 · Disposition to issuer (D): 49,000 (derivative) @ $0 · Disposition to issuer (D): 12,300 (derivative) @ $0 · Disposition to issuer (D): 35,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Norrett Kevin — Chief Business Officer | Disposition to issuer (D): 100,000 (derivative) @ $0 · Disposition to issuer (D): 49,000 (derivative) @ $0 · Disposition to issuer (D): 11,700 (derivative) @ $0 · Disposition to issuer (D): 35,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Oliger Christy J. — Director | Disposition to issuer (D): 18,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Erbez Georgia — Director | Disposition to issuer (D): 18,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner | Disposition to issuer (D): 1,511,362 @ $55 · Disposition to issuer (D): 226,704 @ $55 · Disposition to issuer (D): 226,704 @ $55 · Disposition to issuer (D): 1,136,250 (derivative) @ $0 · Disposition to issuer (D): 170,437 (derivative) @ $0 · Disposition to issuer (D): 170,437 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Norrett Kevin — Chief Business Officer | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Klencke Barbara — Chief Medical Officer | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Jagpal Sukhi — Chief Financial Officer | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | DILLY STEPHEN GEORGE — CEO and President, Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Thomson Mary Christina — General Counsel, CCO & Sec'y | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-04-29 | 4 | Longitude Capital Partners III, LLC — 10% owner Longitude Venture Partners III, L.P. — 10% owner Tammenoms Bakker Juliet — 10% owner ENRIGHT PATRICK G — 10% owner Longitude Prime Partners, LLC — 10% owner Longitude Prime Fund, L.P. — 10% owner | Other (J): 175,000 @ $0 · Other (J): 1,964,771 @ $0 · Other (J): 5,023 @ $0 · Other (J): 2,152 @ $0 · Other (J): 7,175 @ $0 · Other (J): 588 @ $0 · +2 more | EDGAR |
| 2022-04-07 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Option exercise (M): 100 @ $12.05 · Sale (S): 100 @ $37.09 · Option exercise (M): 6,347 @ $12.05 · Sale (S): 6,347 @ $37.25 · Option exercise (M): 100 (derivative) @ $0 · Option exercise (M): 6,347 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Thomson Mary Christina — General Counsel, CCO & Sec'y | Option exercise (M): 2,000 @ $13.04 · Sale (S): 2,000 @ $35.14 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Option exercise (M): 100 @ $12.05 · Sale (S): 100 @ $37.05 · Option exercise (M): 100 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Option exercise (M): 3,453 @ $12.05 · Sale (S): 3,453 @ $37.06 · Option exercise (M): 3,453 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | DILLY STEPHEN GEORGE — CEO and President, Director | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | Jagpal Sukhi — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | Klencke Barbara — Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | Norrett Kevin — Chief Business Officer | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | Thomson Mary Christina — General Counsel, CCO & Sec'y | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2022-03-04 | 4 | Thomson Mary Christina — General Counsel, CCO & Sec'y | Option exercise (M): 2,000 @ $13.04 · Sale (S): 2,000 @ $30.60 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2022-02-08 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Option exercise (M): 10,000 @ $12.05 · Sale (S): 10,000 @ $32.32 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Thomson Mary Christina — General Counsel, CCO & Sec'y | Option exercise (M): 2,000 @ $13.04 · Sale (S): 2,000 @ $29.78 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | Richardson Joshua — Director, 10% owner | Purchase (P): 175,000 @ $27 | EDGAR |
| 2022-02-02 | 4 | Longitude Capital Partners III, LLC — 10% owner Longitude Venture Partners III, L.P. — 10% owner Tammenoms Bakker Juliet — 10% owner ENRIGHT PATRICK G — 10% owner Longitude Prime Partners, LLC — 10% owner Longitude Prime Fund, L.P. — 10% owner | Purchase (P): 175,000 @ $27 | EDGAR |
| 2022-02-01 | 4 | Sinclair Andrew — Director | Option exercise/expiry (X): 287,471 @ $13.20 · Purchase (P): 150,000 @ $27 · Option exercise/expiry (X): 287,471 (derivative) @ $0 | EDGAR |
| 2022-02-01 | 4 | Abingworth LLP — 10% owner | Option exercise/expiry (X): 287,471 @ $13.20 · Purchase (P): 150,000 @ $27 · Option exercise/expiry (X): 287,471 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Vivo Opportunity, LLC — 10% owner Vivo Opportunity Fund, L.P. — 10% owner Vivo Capital IX, LLC — 10% owner Vivo Capital Fund IX, L.P. — 10% owner VIVO VENTURES VII, LLC — 10% owner Vivo Ventures Fund VII, L.P. — 10% owner Vivo Ventures VII Affiliates Fund, L.P. — 10% owner | Purchase (P): 800,000 @ $27 | EDGAR |
| 2022-01-31 | 4 | Aggarwal Gaurav — Director, 10% owner | Purchase (P): 800,000 @ $27 | EDGAR |
| 2022-01-28 | 4 | Kowalski Mark — Chief, Research & Early Dev | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Norrett Kevin — Chief Business Officer | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | DILLY STEPHEN GEORGE — CEO and President, Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Jagpal Sukhi — Chief Financial Officer | Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Thomson Mary Christina — General Counsel & Secretary | Option exercise (M): 2,000 @ $13.04 · Sale (S): 2,000 @ $29 · Option exercise (M): 2,000 (derivative) @ $0 · Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Turner William D. — Chief Reg & Tech Ops Officer | Option exercise (M): 5,000 @ $12.05 · Sale (S): 5,000 @ $27.05 · Option exercise (M): 5,000 (derivative) @ $0 · Grant/award (A): 12,250 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Option exercise/expiry (X): 374,962 @ $13.20 · Option exercise/expiry (X): 56,244 @ $13.20 · Option exercise/expiry (X): 56,244 @ $13.20 · Option exercise/expiry (X): 374,962 (derivative) @ $0 · Option exercise/expiry (X): 56,244 (derivative) @ $0 · Option exercise/expiry (X): 56,244 (derivative) @ $0 | EDGAR |
Recent 8-K events — Sierra Oncology, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-07-01 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2022-06-22 | 8-K | 8.01 — Other Events | EDGAR |
| 2022-06-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2022-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2022-01-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SRRA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs